APA (7th ed.) Citation

TA, D., EC, A., MA, M., MA, S., NA, G., GA, A., . . . DG, A. (2023). Dyslipidemia and serum cystatin C levels as biomarker of diabetic nephropathy in patients with type 2 diabetes mellitus. Frontiers in endocrinology, 14, 1124367. https://doi.org/10.3389/fendo.2023.1124367

Chicago Style (17th ed.) Citation

TA, Dejenie, et al. "Dyslipidemia and Serum Cystatin C Levels as Biomarker of Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus." Frontiers in Endocrinology 14 (2023): 1124367. https://doi.org/10.3389/fendo.2023.1124367.

MLA (9th ed.) Citation

TA, Dejenie, et al. "Dyslipidemia and Serum Cystatin C Levels as Biomarker of Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus." Frontiers in Endocrinology, vol. 14, 2023, p. 1124367, https://doi.org/10.3389/fendo.2023.1124367.